newsfilter
← Latest News
ACCESS Newswire·

MIRA Pharmaceuticals Closes Acquisition of SKNY Pharmaceuticals, Expands Pipeline with SKNY-1 for Obesity and Nicotine Addiction

MIRA
  • MIRA Pharmaceuticals completed its acquisition of SKNY Pharmaceuticals, adding $5 million in marketable securities to strengthen its balance sheet.
  • The transaction expands MIRA's pipeline to include SKNY-1, an oral therapy candidate targeting obesity and nicotine addiction by modulating CB1, CB2, & MAO-B pathways.
  • Preclinical data for SKNY-1 shows up to 30% body weight reduction without muscle loss, reversal of cravings, & a favorable CNS safety profile.
  • MIRA continues advancing Ketamir-2, a non-scheduled ketamine analog that demonstrated safety & tolerability in Phase 1 trials with potential for neuropathic pain, depression, & PTSD.
  • MIRA-55, an oral cannabis-derived candidate, shows preclinical efficacy in inflammatory & nociceptive pain comparable to morphine without addictive risk.
  • MIRA's strategy focuses on differentiated, non-opioid, & non-addictive therapeutic options for major healthcare markets including metabolic disorders, addiction, & pain management.